RY 174.21 0.4845% TD 77.21 -0.3099% SHOP 113.1 0.5155% CNR 157.51 -1.1299% ENB 57.59 0.1565% CP 112.08 -0.5678% BMO 129.49 0.3332% TRI 232.87 0.7921% CNQ 49.045 1.1654% BN 76.23 1.3023% ATD 73.74 -0.6066% CSU 4426.6099 0.3812% BNS 73.69 -0.1896% CM 86.29 0.4657% SU 53.56 0.7714% TRP 65.64 0.845% NGT 78.23 1.1246% WCN 250.66 0.2239% MFC 42.08 -0.1898% BCE 46.14 0.2172%
Last update at 2024-10-17T17:18:00Z
Perimeter Medical Imaging AI Announces CEO Transition and New Member of the Board of Directors
Mon 05 Jun 23, 11:00 AMPerimeter Medical Imaging AI Announces Resignation of Director
Tue 23 May 23, 12:30 PMPerimeter Medical Imaging AI Announces Symposium and Its Participation at ASBrS 2023
Thu 27 Apr 23, 12:30 PMPerimeter Medical Imaging AI Reports 2022 Financial Results and Provides Corporate Update
Tue 11 Apr 23, 08:01 PMBreakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Income before tax | -9.90611M | -16.65177M | -7.88597M | -10.34269M | - |
Minority interest | - | - | - | - | - |
Net income | -9.90611M | -16.65177M | -7.88597M | -10.34269M | - |
Selling general administrative | 10.28M | 11.56M | 8.96M | 7.54M | - |
Selling and marketing expenses | - | - | - | - | - |
Gross profit | 0.10M | 0.00504M | - | - | - |
Reconciled depreciation | 0.80M | 0.09M | 0.05M | 0.05M | - |
Ebit | - | - | -10.06163M | -8.56443M | -5.89451M |
Ebitda | -9.00031M | -16.44763M | -7.73583M | -10.13516M | - |
Depreciation and amortization | - | - | - | - | - |
Non operating income net other | - | - | - | - | - |
Operating income | -16.12131M | -16.05820M | -10.06163M | -8.56443M | - |
Other operating expenses | - | - | 0.48M | 0.39M | 0.31M |
Interest expense | 0.10M | 0.11M | 0.12M | 0.16M | 0.00000M |
Tax provision | 0.00000M | 0.00000M | 0.00000M | 0.00000M | - |
Interest income | - | 0.01M | 0.00690M | 0.00464M | - |
Net interest income | -0.10493M | -0.10049M | -1.72350M | -4.61071M | - |
Extraordinary items | - | - | - | - | - |
Non recurring | - | - | - | - | - |
Other items | - | - | - | - | - |
Income tax expense | - | - | - | - | - |
Total revenue | 0.13M | 0.01M | 0.00000M | 0.00000M | - |
Total operating expenses | 16.25M | 16.07M | 10.06M | 8.56M | - |
Cost of revenue | 0.03M | 0.00630M | - | - | - |
Total other income expense net | 6.32M | -0.49308M | 3.90M | 2.83M | - |
Discontinued operations | - | - | - | - | - |
Net income from continuing ops | -9.90611M | -16.65177M | -7.88597M | -10.34269M | - |
Net income applicable to common shares | - | - | -7.88597M | -10.34269M | -6.50451M |
Preferred stock and other adjustments | - | - | - | - | - |
Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Total assets | 34.60M | 9.98M | 13.16M | 2.55M | - |
Intangible assets | - | - | - | - | - |
Earning assets | - | - | - | - | - |
Other current assets | - | - | - | - | - |
Total liab | 8.49M | 2.56M | 2.40M | 19.03M | - |
Total stockholder equity | 26.11M | 7.42M | 10.76M | -16.47321M | - |
Deferred long term liab | - | - | - | - | - |
Other current liab | 6.04M | - | 0.52M | 2.51M | 2.17M |
Common stock | - | - | 48.50M | 17.80M | 13.54M |
Capital stock | 80.84M | 62.47M | 48.50M | 17.80M | - |
Retained earnings | -59.32298M | -63.98144M | -47.32967M | -39.44370M | -29.10102M |
Other liab | - | - | 0.27M | 0.28M | 0.42M |
Good will | - | - | - | - | - |
Other assets | - | - | - | - | - |
Cash | 28.44M | 4.72M | 10.03M | 1.21M | - |
Cash and equivalents | - | - | - | - | - |
Total current liabilities | 8.04M | 2.15M | 1.82M | 18.54M | 15.05M |
Current deferred revenue | - | - | - | - | - |
Net debt | - | - | - | 12.98M | - |
Short term debt | - | - | - | - | - |
Short long term debt | 0.11M | 0.13M | 0.05M | 13.99M | - |
Short long term debt total | - | - | - | - | - |
Other stockholder equity | - | - | 0.18M | - | - |
Property plant equipment | - | - | 0.08M | 0.07M | 0.04M |
Total current assets | 31.50M | 7.74M | 13.07M | 2.48M | 2.90M |
Long term investments | - | - | - | - | - |
Net tangible assets | - | - | 10.76M | -16.47703M | -12.90771M |
Short term investments | 0.00000M | 0.42M | 1.67M | 0.00000M | - |
Net receivables | 0.07M | - | 0.60M | 1.01M | 0.85M |
Long term debt | 0.00965M | 0.16M | 0.29M | 0.20M | - |
Inventory | 0.04M | 0.00649M | - | - | - |
Accounts payable | - | - | 1.21M | 2.03M | 0.63M |
Total permanent equity | - | - | - | - | - |
Noncontrolling interest in consolidated entity | - | - | - | - | - |
Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
Accumulated other comprehensive income | - | - | - | - | - |
Additional paid in capital | - | - | - | - | - |
Common stock total equity | - | - | - | - | - |
Preferred stock total equity | - | - | - | - | - |
Retained earnings total equity | - | - | - | - | - |
Treasury stock | - | - | - | - | - |
Accumulated amortization | - | - | - | - | - |
Non currrent assets other | - | - | - | - | - |
Deferred long term asset charges | - | - | - | - | - |
Non current assets total | 3.10M | 2.25M | 0.09M | 0.07M | - |
Capital lease obligations | 0.21M | 0.15M | 0.06M | 0.02M | - |
Long term debt total | - | - | - | - | - |
Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Investments | -1.74879M | -1.44806M | 6.33M | 6.33M | 6.33M |
Change to liabilities | 0.00000M | -0.90960M | -0.16156M | 1.06M | 0.75M |
Total cashflows from investing activities | - | - | 7.24M | -0.04695M | -0.05385M |
Net borrowings | - | - | -0.14109M | 1.11M | -0.03076M |
Total cash from financing activities | 40.28M | 10.06M | 9.84M | 5.20M | -0.02976M |
Change to operating activities | - | -0.48625M | -0.51238M | -0.05025M | -0.02387M |
Net income | -9.90611M | -16.65177M | -7.88597M | -10.34269M | -6.50451M |
Change in cash | 26.67M | -5.30512M | 8.81M | -0.63541M | -4.17138M |
Begin period cash flow | 3.72M | 10.03M | 1.21M | 1.85M | - |
End period cash flow | 28.44M | 4.72M | 10.03M | 1.21M | 1.85M |
Total cash from operating activities | -11.86791M | -13.91239M | -8.26299M | -5.78515M | -4.08777M |
Issuance of capital stock | 38.14M | 0.00000M | 9.41M | 4.08M | - |
Depreciation | 0.80M | 0.09M | 0.05M | 0.05M | 0.03M |
Other cashflows from investing activities | - | - | - | - | - |
Dividends paid | - | - | - | - | - |
Change to inventory | -0.03785M | -0.00649M | - | - | - |
Change to account receivables | -0.07200M | 0.27M | -0.26346M | 0.19M | -0.17858M |
Sale purchase of stock | - | - | - | - | - |
Other cashflows from financing activities | 0.42M | 0.42M | 1.62M | -0.30615M | -0.30615M |
Change to netincome | - | - | 0.50M | 3.07M | 1.84M |
Capital expenditures | 1.99M | 2.12M | 0.00000M | 0.05M | 0.05M |
Change receivables | - | - | - | - | - |
Cash flows other operating | - | - | - | - | - |
Exchange rate changes | - | - | - | - | - |
Cash and cash equivalents changes | - | - | - | - | - |
Change in working capital | -0.22628M | 0.41M | -0.93740M | 1.21M | - |
Stock based compensation | 1.52M | 3.13M | 2.25M | 1.32M | - |
Other non cash items | -2.51166M | -0.90003M | -1.84445M | 1.98M | - |
Free cash flow | -13.85927M | -16.03478M | -8.26299M | -5.83210M | - |
Sector: Healthcare Industry: Medical Devices
Company | Change (CAD) | Price (CAD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
---|---|---|---|---|---|---|---|---|
PINK Perimeter Medical Imaging AI Inc |
0.02 3.70% | 0.56 | - | - | 117.72 | 2.89 | 122.12 | -4.2252 |
VPT VentriPoint Diagnostics Ltd |
-0.015 8.11% | 0.17 | - | - | 1376.49 | 34.01 | 1193.16 | -9.1712 |
TLT Theralase Technologies Inc. |
-0.005 2.63% | 0.18 | - | - | 35.41 | 23.10 | 36.69 | -9.1528 |
ASG Aurora Spine Corp |
0.02 6.67% | 0.32 | - | - | 1.83 | 5.11 | 2.14 | -31.4665 |
NGMD NuGen Medical Devices Inc |
- -% | 0.10 | - | - | 107.75 | 9.71 | 118.72 | -4.5025 |
Perimeter Medical Imaging AI, Inc., a medical technology company, develops and commercializes advanced imaging tools that allow surgeons, radiologists, and pathologists to visualize microscopic tissue structures during a clinical procedure. The company offers an optical coherence tomography (OCT) imaging system provides clinicians with cross-sectional of tissues down to 2 mm dept. This OCT imaging system consists of S-series OCT and B-series OCT. It also offers ImgAssist, an artificial intelligence technology that enhances the efficiency of image review and be an additional powerful tool when combined with Perimeter OCT to aid physicians with real-time margin visualization and assessment to improve surgical outcomes for patients and reducing the likelihood of needing additional surgeries. In addition, the company offers proprietary image library and consumable specimen containers to hospitals and cancer surgery centers. The company was founded in 2013 and is headquartered in Toronto, Canada.
359 Eastern Avenue, Toronto, ON, Canada, M4M 1B7
Name | Title | Year Born |
---|---|---|
Mr. Jeremy Sobotta | CEO, Pres & Director | NA |
Mr. Merle Thomas Boon | Chief Operating Officer | NA |
Mr. Andrew Berkeley | Co-Founder & Head of Bus. Devel. | NA |
Mr. Christopher K. Scott | Chief Financial Officer | 1970 |
Mr. Vladimir Pekar | Head of AI Algorithm Devel. | NA |
Ms. Rochelle Keen | Head of Clinical Research Programs | NA |
Mr. Steve Sapot | Chief Commercial Officer | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.